Literature DB >> 27076970

Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.

Matthijs H van Gool1, Tjeerd S Aukema1, Michiel Sinaasappel1, Renato A Valdés Olmos1, Houke M Klomp1.   

Abstract

Response monitoring using fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) textural features has potential in targeted treatment with erlotinib in non-small cell lung cancer (NSCLC) patients. Patients with substantial decrease of metabolic activity during erlotinib treatment will probably benefit from continued treatment. However, various aspects of the method (quantification tools, cut-off values, etc.) need to be standardized before the software becomes widely available in a similar manner as standardized uptake value (SUV) measurements. Heterogeneity on FDG-PET/CT opened an additional window for innovation but simultaneously a new challenge for molecular hybrid imaging.

Entities:  

Keywords:  Fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT); epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI); non-small cell lung cancer (NSCLC)

Year:  2016        PMID： 27076970      PMCID： PMC4805797          DOI： 10.21037/jtd.2016.02.10

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  20 in total

Review 1.  PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.

Authors:  Mia Schmidt-Hansen; David R Baldwin; Elise Hasler; Javier Zamora; Víctor Abraira; Marta Roqué I Figuls
Journal:  Cochrane Database Syst Rev       Date:  2014-11-13

2.  Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions.

Authors:  N C Gupta; G M Graeber; H A Bishop
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

3.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

4.  Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls.

Authors:  Akira Toriihara; Yoshio Kitazume; Hidenori Nishida; Kazunori Kubota; Masashi Nakadate; Ukihide Tateishi
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

5.  Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.

Authors:  Humberto Lara-Guerra; Catherine T Chung; Joerg Schwock; Melania Pintilie; David M Hwang; Natasha B Leighl; Thomas K Waddell; Ming-Sound Tsao
Journal:  Lung Cancer       Date:  2011-11-22       Impact factor: 5.705

Review 6.  EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.

Authors:  Jean-Charles Soria; Tony S Mok; Federico Cappuzzo; Pasi A Jänne
Journal:  Cancer Treat Rev       Date:  2011-11-25       Impact factor: 12.111

7.  Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.

Authors:  Akihiko Kawahara; Chizuko Yamamoto; Kazutaka Nakashima; Koichi Azuma; Satoshi Hattori; Masaki Kashihara; Hisamichi Aizawa; Yuji Basaki; Michihiko Kuwano; Masayoshi Kage; Tetsuya Mitsudomi; Mayumi Ono
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

Review 8.  Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

Authors:  C Gridelli; F De Marinis; M Di Maio; D Cortinovis; F Cappuzzo; T Mok
Journal:  Lung Cancer       Date:  2011-01-08       Impact factor: 5.705

9.  Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.

Authors:  Matthijs H van Gool; Tjeerd S Aukema; Eva E Schaake; Herman Rijna; Renato A Valdés Olmos; Renée van Pel; Sjaak A Burgers; Harm van Tinteren; Houke M Klomp
Journal:  J Nucl Med       Date:  2014-05-08       Impact factor: 10.057

10.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728
View more
  3 in total

Review 1.  Clinical applications of textural analysis in non-small cell lung cancer.

Authors:  Iain Phillips; Mazhar Ajaz; Veni Ezhil; Vineet Prakash; Sheaka Alobaidli; Sarah J McQuaid; Christopher South; James Scuffham; Andrew Nisbet; Philip Evans
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

2.  Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC.

Authors:  Xiaofeng Li; Guotao Yin; Yufan Zhang; Dong Dai; Jianjing Liu; Peihe Chen; Lei Zhu; Wenjuan Ma; Wengui Xu
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

3.  Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Authors:  Sehhoon Park; Seunggyun Ha; Se-Hoon Lee; Jin Chul Paeng; Bhumsuk Keam; Tae Min Kim; Dong-Wan Kim; Dae Seog Heo
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.